Table 1.
N | 636 |
| |
Length of follow-up (years), median (IQR) | 1.58 (.8, 3.4) |
| |
Neuropathy Cumulative Incidence, n (%) | 261 (41%) |
| |
Demographic Variables | |
| |
Age (years), median (IQR) |
41.0 (36.0,46.8) |
Male, n (%) | 489 (77%) |
| |
Race/Ethnicity, n (%) | |
White | 227 (36%) |
Black | 189 (30%) |
Hispanic | 193 (30%) |
Other |
27 (4%) |
HIV-related variables | |
| |
History of d-drug use, n (%) |
413 (65%) |
Current d-drug use, n (%) | 230 (36%) |
| |
Median HIV duration (years), median (IQR) |
10 (5, 15) |
Laboratory parameters | |
| |
CD4+ count (cells/mm3), median (IQR) |
131 (39, 283) |
HIV plasma RNA (log10(copies/ml)), median (IQR) | 3.3 (2.6, 4.7) |
| |
Hemoglobin (g/dL), median (IQR) |
13.3 (12.0, 14.5) |
Glucose mg/dL, median (IQR) | 89 (76, 102) |
| |
Substance use variables | |
| |
Any criteria for substance usea, n (%) | 489 (77%) |
| |
Reported intravenous drug use as a risk factor for HIV-infection, n (%) |
162 (25%) |
Urine toxicology positive, n (%) | 194 (31%) |
| |
DSM-IV diagnosis of past or current substance abuse or dependence of any substance, n (%) |
427 (67%) |
Individual substances usedb, n (%) | |
| |
Alcohol |
291 (46%) |
Cocaine | 292 (46%) |
| |
Cannabis |
265 (42%) |
Opiates | 117 (18%) |
| |
Stimulants |
150 (24%) |
Hallucinogens | 40 (6%) |
| |
Sedatives |
82 (15%) |
Other | 29 (5%) |
| |
Severity of use (for any substance) |
|
Abuse diagnosis or urine toxicology positive | 95 (15%) |
| |
Dependence diagnosis |
370 (58%) |
Number of substancesb, n (%) | |
| |
0 | 154 (24%) |
| |
1 | 124 (20%) |
| |
2–3 | 226 (36%) |
| |
4 or more | 115 (18%) |
Includes a DSM-IV diagnosis, self-report of intravenous drug use, or positive urine toxicology.
Defined as a DSM-IV diagnosis or urine toxicology positive for an individual substance.